About RadaHaim

RadaHaim has developed a high-throughput organoid assay system that enables the automated production of organoids tailored to specific tumor and cell types for drug screening. This technology addresses the inefficiencies in the drug discovery process by providing accurate disease models that bridge the gap between basic research and clinical trials.

```xml <problem> The drug discovery process suffers from inefficiencies due to inaccurate disease models that fail to bridge the gap between basic research and clinical trials. Traditional drug screening methods often lack the complexity and physiological relevance needed to accurately predict drug efficacy and toxicity in humans. </problem> <solution> RadaHaim offers a high-throughput organoid assay system that automates the production of organoids tailored to specific tumor and cell types for drug screening. This technology provides more accurate and relevant disease models, improving the efficiency and effectiveness of drug discovery. By creating organ-on-a-panel and body-on-a-chip solutions, RadaHaim enables researchers to conduct toxicity and efficacy tests, study disease mechanisms at the organism level, and develop alternative clinical trial models for rare diseases. The automated, large-scale production protocol facilitates innovation in the biopharmaceutical sector. </solution> <features> - Automated organoid production for various cell and tumor types (liver, heart, kidney) - Organ-on-a-panel for toxicity and efficacy testing of new drugs - Body-on-a-chip for studying the effects of specific diseases at the organism level - Alternative to clinical trial chip for new drugs targeting rare diseases - High-throughput screening capabilities for large-scale drug discovery </features> <target_audience> The primary audience includes biopharmaceutical companies and research institutions involved in drug discovery and development, particularly those focused on oncology and rare diseases. </target_audience> ```

What does RadaHaim do?

Where is RadaHaim located?

RadaHaim is based in 성남시, 대한민국.

When was RadaHaim founded?

RadaHaim was founded in 2022.

How much funding has RadaHaim raised?

RadaHaim has raised $2.5M.

Location

성남시, 대한민국

Founded

2022

Funding

$2.5M

Employees

1 employees

RadaHaim

성남시, 대한민국Founded 2022150+ followers3/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 3 months ago

Funding

$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

The drug discovery process suffers from inefficiencies due to inaccurate disease models that fail to bridge the gap between basic research and clinical trials. Traditional drug screening methods often lack the complexity and physiological relevance needed to accurately predict drug efficacy and toxicity in humans.

Solution

RadaHaim offers a high-throughput organoid assay system that automates the production of organoids tailored to specific tumor and cell types for drug screening. This technology provides more accurate and relevant disease models, improving the efficiency and effectiveness of drug discovery. By creating organ-on-a-panel and body-on-a-chip solutions, RadaHaim enables researchers to conduct toxicity and efficacy tests, study disease mechanisms at the organism level, and develop alternative clinical trial models for rare diseases. The automated, large-scale production protocol facilitates innovation in the biopharmaceutical sector.

Target Audience

The primary audience includes biopharmaceutical companies and research institutions involved in drug discovery and development, particularly those focused on oncology and rare diseases.

Features

Automated organoid production for various cell and tumor types (liver, heart, kidney)
Organ-on-a-panel for toxicity and efficacy testing of new drugs
Body-on-a-chip for studying the effects of specific diseases at the organism level
Alternative to clinical trial chip for new drugs targeting rare diseases
High-throughput screening capabilities for large-scale drug discovery